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A b s t R A C t
bACkgRoUnd: Cardiovascular inflammation has emerged as a key pathogenetic fac-
tor in coronary artery disease (CAD) and myocardial ischemia reperfusion injury. 
Ischemia reperfusion injury complicates all forms of coronary artery revasculariza-
tion. Cardiac mast cells have been implicated in CAD, reperfusion injury and myo-
cardial infarction (MI) through the release of pro-arrhythmogenic and inflammatory 
mediators, especially interleukin-6 (IL-6), considered an independent risk factor.
objECtIVE: Review evidence supporting the role of mast cells in cardiovascular 
pathophysiology.
MEthods: We reviewed relevant literature and summarized our own findings.
REsUlts: We showed that CAD is associated with high intracoronary release of IL-6. 
Acute stress triggers mast cell- dependent release of histamine and IL-6. Moreover, 
acute stress in ApoE -/- mice leads to ischemia. Mast cells express corticotropin-re-
leasing-hormone (CRH) receptors, activation of which leads to selective release of 
vascular endothelial growth factor (VEGF), an isoform of which is vasodilatory. In 
a randomized prospective study, we investigated serum IL-6 levels and cardiac tissue 
susceptibility in the mast cell deficient (W/Wv) mice (n=12) and their normal litter-
mates (+/+). When the left coronary artery (LCA) was ligated followed by 6 hours of 
reperfusion, IL-6 levels increased significantly after reperfusion only in the +/+ mice, 
but not in mast cell deficient W/Wv mice; cardiac muscle viability was significantly 
higher in W/Wv than the +/+ mice.
ConClUsIon: These results support targeting selective inhibition of cardiac mast cell 
activation as prophylactic therapy in clinical situations involving myocardial inflam-
mation and/or revascularization.
1 .  s E l E C t I V E  R E l E A s E  o f  M A s t  C E l l  M E d I A t o R s
Mast cells derive from a distinct precursor in the bone marrow1 and mature under 
local tissue micro-environmental factors.2 Mast cells are necessary for the development 
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of allergic reactions, through cross-linking of their surface 
receptors for IgE (FcRI), leading to degranulation and 
the release of vasoactive, pro-inflammatory and nociceptive 
mediators that include histamine, cytokines and proteolytic 
enzymes (Table 1).3,4 The multitude of mediators that could 
be secreted, especially in response to many non-immunologic 
triggers (Table 2) has given rise to new speculations about the 
possible role of mast cells in immune responses, especially 
acquired immunity5 and inflammation.6
Unlike allergic reactions, mast cells are rarely seen to 
degranulate during autoimmune7 or inflammatory processes.8 
Instead, mast cells can secrete mediators without overt de-
granulation,9 through differential or selective release,10 prob-
ably regulated by the action of distinct protein kinases on a 
unique phosphoprotein.11,12 In such cases, mast cells undergo 
ultrastructural alterations of their electron dense granular 
core indicative of secretion, but without overt degranulation, 
a process that has been termed “activation”13-15 “intragranular 
activation”16 or “piecemeal” degranulation.17 Selective release 
has been reported for a number of mediators,18-20 especially 
serotonin,10 eicosanoids21-23 or IL-6.24-27 In fact, we showed 
that interleukin-1 (IL-1) can stimulate human mast cells to 
release IL-6 selectively without degranulation, through a 
unique process utilizing 40-80 nm vesicles unrelated to the 
secretory granules (800-1000 nm).28 We also recently showed 
that corticotropin releasing hormone (CRH) secreted un-
der stress can stimulate human mast cells through specific 
CRH receptors to release vascular endothelial growth factor 
(VEGF) selectively.29
These findings suggest that mast cells may also be involved 
in inflammatory diseases6,30 that include migraines31 and 
cardiovascular disease.32
2 .  C A R d I o V A s C U l A R  I n f l A M M A t I o n
Increasing evidence implicates acute psychological stress 
and cardiac mast cells in cardiovascular pathology, especially 
unstable angina and silent myocardial ischemia (MI). Myo-
cardial infarction occurring without angina on presentation 
now appears to be a sizable portion of the MI population.33-36 
Allergic angina and MI have also been reported.37 Mast cells 
have also recently been implicated in coronary microemboliza-
tion and cardiomyocyte apoptosis.38 There is growing evidence 
that cardiac mast cells39 participate in the development of 
atherosclerosis, coronary inflammation and cardiac ischemia. 
Mast cells have been identified in coronary arteries during 
spasm,40 and accumulate in the shoulder region of human 
coronary atheromas, especially in association with plaque rup-
ture.32,41,42 The human mast cell proteolytic enzyme chymase 
has been shown to be the main cardiac source of converting 
enzyme generating the coronary constrictor angiotensin II.43 
Chymase can also promote cholesterol removal from HDL and 
deposition on foam cells.44-46 Mast cells tryptase can induce 
wide-spread inflammation through stimulation of protease-
activated receptors (PAR).47 Tryptase is also a biomarker in 
patients with stable CAD.48 Cardiac mast cell-derived hista-
mine49 can constrict the coronaries50 and can sensitize nerve 
endings;51 this action is rendered probable by the recent find-
ings showing adventitial mast cells localized close to nerve 
endings in atherosclerotic coronary arteries.52
Acute stress induced rat cardiac mast cell activation 
documented morphologically.53 It was later shown that acute 
stress induced histamine release from mouse heart,54 as well as 
serum histamine and IL-6 elevations;54,55 these were greater in 
apolipoprotein E (ApoE) knockout mice that develop athero-
sclerosis, but were still entirely dependent on mast cells.54,55 
These findings are significant since serum IL-6 elevations in 
patients with acute MI were shown to derive primarily from the 
coronary sinus.56 Both histamine57 and IL-658 are significant 
predictive risk factors of coronary events.
We also recently showed that ischemia reperfusion in mice 
increased serum IL-6 and myocardial necrosis, but not in 
W/Wv mast cell deficient mice.59 Such results have prompted 
editorials implicating mast cells CAD and MI.60
C o n C l U s I o n
In summary, the mast cell has emerged as a unique 
immune cell that could be activated by many non-immune 
processes, including acute stress,61,62 and could participate in 
CAD and MI (Fig. 1).
tAblE 1. Mast cell Triggers
Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences
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tAblE 2. Mast Cell Mediators
Mediators Main Pathophysiologic Effects
Prestored
biogenic Amines
Histamine Vasodilation, angiogenesis, mitogenesis, pain
5-Hydroxytryptamine (5-HT, serotonin) Vasoconstriction, pain
Chemokines
IL-8, MCP-1, MCP-3, MCP-4, RANTES Chemoattraction and tissue infiltration of leukocytes
Enzymes
Arylsulfatases Lipid/proteoglycan hydrolysis
Carboxypeptidase A Peptide processing
Chymase Tissue damage, angiotensin II synthesis, cholesterol liberation
Kinogenases Synthesis of vasodilatory kinins, pain
Phospholipases Arachidonic acid generation
Tryptase Tissue damage, activation of PAR, inflammation, pain
Peptides
Corticotropin-releasing hormone (CRH) Inflammation, vasodilation
Endorphins Analgesia
Endothelin Sepsis
Kinins (bradykinin) Inflammation, pain, vasodilation
Somatostatin (SRIF) Anti-inflammatory (?)
Substance P (SP) Inflammation, pain
Vasoactive intestinal peptide (VIP) Vasodilation
Urocortin Inflammation, vasodilation
Vascular endothelial growth factor (VGEF) Neovascularization, vasodilation
Proteoglycans
Chondroitin sulfate Cartilage synthesis, anti-inflammatory
Heparin Angiogenesis, nerve growth factor stabilization
Hyaluronic acid Connective tissue, nerve growth factor stabilization
de novo synthesized
Cytokines
Interleukins (IL)-1,2,3,4,5,6,9,10,13,16 Inflammation, leukocyte migration, pain
INF-γ; MIF; TNF-α Inflammation, leukocyte proliferation/activation
growth factors
SCF, GM-CSF, b-FGF, NGF, VEGF Growth of a variety of cells
Phospholipid metabolites
Leukotriene B4 LTB4 Leukocyte chemotaxis
Leukotriene C4 (LTC4) Vasoconstriction, pain
Platelet activating factor (PAF) Platelet activation, vasodilation
Prostaglandin D2 (PGD2) Bronchonstriction, pain
nitric oxide (no) Vasodilation
CRH = corticotropin-releasing hormone TGF-β = transforming growth factor-β
CSF = colony stimulating factor TNF-α = tumor necrosis factor-α
INFγ = Interferon-γ SRIF = somatomedin release inhibitory factor, somatostatin
MIF = macrophage inflammatory factor GM-CSF = granulocyte monocyte-colony stimulating factor
b-FGF = fibroblast growth factor NGF = nerve growth factor
SCF = Stem cell factor VEGF = vascular endothelial growth factor
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